X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

By Jim C. Stansel  |    July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...   Read More

Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

By Guest Contributor  |    June 28, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Medicare Part D cliff ahead

By Juliet Johnson  |    June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...   Read More

Aspen Spotlight Health: Discussing the forefront of innovation

By Katie Koziara  |    June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...   Read More

Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014

By Holly Campbell  |    June 20, 2018
Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

Long-awaited FDA guidance addresses one key obstacle to value-based contracting

By Jim C. Stansel  |    June 19, 2018
As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical...   Read More

ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

By Nicole Longo  |    June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...   Read More

Part D cliff looms for seniors, as program stability could be in jeopardy

By Juliet Johnson  |    June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...   Read More

Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill

By Andrew Powaleny  |    June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates